Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shelly Martinek

Physician Assistant Chico, CA Physician Assistant

NPI 1255483160 CMS profile 10639447

181 E 7Th Ave, Chico, CA 95926

Open in the dashboard

General payments

$4,828

113 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shelly Martinek of Chico, CA is reported in the CMS Open Payments database as having received $4,828 across 113 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $181 4
2024 General $2,539 14
2023 General $584 22
2022 General $981 48
2021 General $544 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelly Martinek
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Shelly Martinek were reported at $181. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Shelly Martinek Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $544 $132 $37–$438 $132
2022 $981 $155 $48–$522 $149
2023 $584 $167 $52–$557 $160
2024 $2,539 $178 $55–$600 $164
2025 $181 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Edwards Lifesciences Corporation $2,566 14 payments
  2. Janssen Pharmaceuticals, Inc $805 41 payments
  3. Novartis Pharmaceuticals Corporation $234 12 payments
  4. Abbott Laboratories $171 1 payment
  5. Esperion Therapeutics, Inc. $139 8 payments
  6. Boston Scientific Corporation $123 1 payment
  7. Merck Sharp & Dohme Corporation $123 8 payments
  8. Sanofi-Aventis U.S. LLC $119 6 payments
  9. Medtronic, Inc. $88 1 payment
  10. Maquet Cardiovascular U.S. Sales, L.L.C. $85 1 payment
  11. Other $376 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,828 107 payments
  2. Travel and Lodging $1,856 3 payments
  3. Education $144 3 payments
Products named General payments · program years 2021–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $2,430 12 payments
  2. XARELTO $802 40 payments
  3. MITRACLIP $171 1 payment
  4. NEXLETOL $139 8 payments
  5. WATCHMAN FLX $123 1 payment
  6. VERQUVO $123 8 payments
  7. ENTRESTO $91 5 payments
  8. VenaSeal $88 1 payment
  9. Acrobat-I Stabilizer $85 1 payment
  10. LEQVIO $83 4 payments
  11. Other $710 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,545

Median for Physician Assistant: 241

Drug cost

$552,987

Median for Physician Assistant: $4,110

Branded share of claims

25.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 312 $406,980
Xarelto Rivaroxaban Brand 41 $55,268
Entresto Sacubitril/Valsartan Brand 29 $39,458
Multaq Dronedarone Hcl Brand 15 $16,199
Metoprolol Succinate Generic 423 $8,164
Ezetimibe Generic 54 $3,378
Atorvastatin Calcium Generic 284 $2,911
Ranolazine Er Ranolazine Brand 21 $2,239
Losartan Potassium Generic 167 $1,587
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 45 $1,474

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$31,497

Medicare's payments for the services billed

Medicare patients

342

Average age 76

Services billed

563

198 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 40%
Arthritis 39%
Atrial fibrillation 35%
Diabetes 29%
Chronic kidney disease 28%
Heart failure 24%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

113 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record